Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters

BACKGROUND: Vitamin D deficiency is a common side effect of imatinib mesylate (IM) therapy. Transporter polypeptides involved in the disposition of IM may be required for maintenance of adequate vitamin D concentrations. OBJECTIVE: The aim of the present work is to study the association between the...

Descripción completa

Detalles Bibliográficos
Autores principales: Omran, Mervat M., Shouman, Samia A., Abdelfattah, Raafat, Moussa, Heba S., Thabet, Nadia A., Hamza, Marwa S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519432/
https://www.ncbi.nlm.nih.gov/pubmed/36188630
http://dx.doi.org/10.1016/j.curtheres.2022.100684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519432/
https://www.ncbi.nlm.nih.gov/pubmed/36188630
http://dx.doi.org/10.1016/j.curtheres.2022.100684

Ejemplares similares